FGFR1 and adenocarcinoma: Reported FGFR1 amplification frequencies in studies on 32–189 esophageal cancers range between 6–21% in squamous cell cancers [24,25] and 9% in adenocarcinomas [25], but the impact on patient prognosis is largely unknown.